Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

205.47 -1.85 (-0.89%)

Streaming Delayed Price Updated: 3:47 PM EST, Dec 23, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

99 100 Next >

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

June 10, 2025

From Johnson & Johnson

Via Business Wire

Rep. Gilbert Ray Cisneros Has Bought Up to $410K Worth Of Johnson & Johnson Stock: Here's What You Should Know ↗

June 09, 2025

Via Benzinga

3 Top Dividend Stocks Analysts Are Bullish on Right Now

June 06, 2025

With earnings season coming to an end, investors are looking for new catalysts; here are three blue-chip companies with strong analyst support

Via MarketBeat

Topics ETFs

12 Analysts Have This To Say About Johnson & Johnson ↗

June 05, 2025

Via Benzinga

P/E Ratio Insights for Johnson & Johnson ↗

May 28, 2025

Via Benzinga

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug ↗

June 05, 2025

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

Via Benzinga

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point ↗

June 04, 2025

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.

Via Benzinga

Johnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation ↗

June 03, 2025

Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple myeloma patients.

Via Benzinga

5 Cheap Stocks to Buy in June ↗

June 03, 2025

These stocks are ready for a summer surge.

Via The Motley Fool

Top 3 Reasons Savvy Investors Are Buying Johnson & Johnson Stock While Others Panic Over Lawsuits ↗

May 31, 2025

For long-term investors looking for both stability and innovation in the healthcare space, JNJ is a rare combination of both.

Via Talk Markets

Michael Mahoney Turned Boston Scientific Into A Medical Tech Empire ↗

May 29, 2025

Michael Mahoney's grandfather was a cardiac surgeon — so his first career plan was to become a doctor. Mahoney didn't give up — he adjusted.

Via Investor's Business Daily

3 Elite High-Yield Dividend Stocks Down 8% to 27% That Have Hiked Their Payouts for More than 50 Years in a Row ↗

May 29, 2025

Via The Motley Fool

Topics Bonds

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 28, 2025

From Johnson & Johnson

Via Business Wire

Why Is Teva Stock Trading Higher On Tuesday? ↗

May 27, 2025

Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.

Via Benzinga

Why Dan Loeb Just Made Kenvue One Of His Top Holdings ↗

May 27, 2025

Activist investor Dan Loeb's Third Point LLC acquired a significant stake in consumer health company Kenvue Inc. in Q1 2025.

Via Benzinga

1 Top Dividend Stock to Buy for a Lifetime of Passive Income ↗

May 27, 2025

Via The Motley Fool

Topics Economy Lawsuit

Johnson & Johnson (NYSE:JNJ) – A Reliable Dividend Stock Worth Considering ↗

May 26, 2025

Johnson & Johnson (NYSE:JNJ) offers a strong dividend yield, consistent growth, and solid profitability, making it a compelling choice for income investors.

Via Chartmill

Investing for Passive Income? Here's What History Says About the Stability of Dividend King Stocks. ↗

May 25, 2025

Via The Motley Fool

Generating Passive Income: 3 Top Dow Dividend Stocks to Buy for 2025 and Beyond ↗

May 24, 2025

Via The Motley Fool

Topics Bonds Stocks

Elon Musk Commits to Tesla. Is That a Good Thing? ↗

May 23, 2025

Via The Motley Fool

Value Investing Is Not Dead - It Just Got Smarter ↗

May 23, 2025

Via Benzinga

FDA Panel Reiterates the Cancer Risks of Talc

May 23, 2025

From Beasley Allen Law Firm

Via Business Wire

This Healthy High-Yielding Dividend Stock Just Increased Its Payment for the 48th Year in a Row ↗

May 23, 2025

Via The Motley Fool

Topics World Trade

3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market

May 22, 2025

For buy-and-hold investors looking for some quality names to navigate a turbulent market, here are three stocks to consider

Via MarketBeat

Topics ETFs Economy

Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference

May 21, 2025

From Johnson & Johnson

Via Business Wire

Apple, Nvidia, GM: CEOs Are Talking About Being American-Made Again ↗

May 20, 2025

US companies are reshoring manufacturing operations & investing billions in the country, led by Apple & Nvidia for tech, J&J & Eli Lilly for healthcare, Anheuser-Busch for beer, & Cra-Z-Art for toys....

Via Benzinga

Market Whales and Their Recent Bets on JNJ Options ↗

May 19, 2025

Via Benzinga

Meet the Warren Buffett Investment That's Gained 5,502,284% and Looks Set to Soar Even Higher ↗

May 18, 2025

Warren Buffett has had a lot of successful investments, but one in particular has crushed the stock market time and again.

Via The Motley Fool

3 Magnificent Stocks That Are Passive Income Machines ↗

May 17, 2025

Via The Motley Fool

US-China Trade Truce, Trump's Middle East Deals Spark Wall Street Rally: This Week In Markets ↗

May 16, 2025

U.S. and China cut tariffs by 115 points, sparking a stock rally and improving trade outlook. Trump secures $2 trillion in Gulf deals.

Via Benzinga

Topics Government World Trade

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Johnson & Johnson (NY:JNJ)

All News about Johnson & Johnson

Starting at $3.75/week.

Subscribe Today